Tuesday, January 18, 2011
Phase II trial of sequential paclitaxel and 1?h infusion of bryostatin-1 in patients with advanced esophageal cancer
BackgroundWe sought to determine the response rate and toxicity profile of sequential paclitaxel and bryostatin-1, a novel, selective inhibitor of protein kinase C, in patients with advanced esophageal cancer.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment